Studies using cDNA microarrays have consistently shown decreased RGS4 expression in the prefrontal cortex of subjects with schizophrenia, suggesting implications for CBD in anxiety and mental disorder therapies (McGuire et al. 2018). This evidence concerns the gene RGS4 and schizophrenia.